Variables | Microscopic infected women n = 27 | Submicroscopic infected women n = 223 | p value |
---|---|---|---|
Age in years (median with IQR) | 23 (20; 27) | 25 (21; 31) | 0.027 |
≤ 20 years | 7/27 (25.9%) | 44/223 (19.7%) | 0.45 |
21–30 years | 18/27 (66.7%) | 118/223 (52.9%) | 0.22 |
> 30 years | 2/27 (7.4%) | 60/223 (26.9%) | 0.03 |
Parity (mean ± SD) | 2.1 ± 1.0 | 2.7 ± 1.5 | 0.05 |
Gravidity (mean ± SD) | 2.2 ± 1.1 | 3.2 ± 1.7 | 0.008 |
Primigravidae | 8/27 (29.6%) | 42/223 (18.8%) | 0.20 |
Secundigravidae | 8/27 (29.6%) | 47/223 (21.1%) | 0.33 |
Multigravidae | 11/27 (40.7%) | 134/223 (60.0%) | 0.06 |
Haemoglobin level in (g/dL) (median with IQR) | 10.05 (8.45; 12.60) | 11.60 (10.30; 13.00) | 0.011 |
Maternal anaemia (Hb < 11 g/dL) | 16/26 (61.5%) | 80/221 (36.2%) | 0.02 |
Gestational age in weeks (median with IQR) | 38 (36; 39) | 38 (37; 39) | 0.06 |
msp-1 DNA positive individuals | 27 (100%) | 223 (100%) | 1 |
Preterm delivery (GA < 37 weeks) | 7/27 (25.9%) | 39/223 (17.5%) | 0.28 |
Birth weight in g (mean ± SD) | 3081 ± 0.449 | 3130 ± 0.482 | 0.62 |
Baby low birth weight | 2/27 (7.4%) | 17/223(7.6%) | 1.00 |
IPT-SP usage | |||
Doses of SP (mean ± SD) | 1.2 ± 0.9 | 1.7 ± 1.0 | 0.020 |
0 Dose of SP | 6/27 (22.2%) | 54/343 (15.7%) | 0.41 |
1 Dose of SP | 13/27 (48.1%) | 90/343 (26.2%) | 0.02 |
2 Doses of SP | 4/27 (14.8%) | 91/343 (26.5%) | 0.25 |
3 Doses of SP | 4/27 (14.8%) | 108/343 (31.9%) | 0.08 |
Women using ITNs | 27/27 (100%) | 222/343 (64.7%) | < 0.0001 |